RIDGEFIELD, Conn., May 8, 2012 /PRNewswire/ -- Boehringer Ingelheim will present the latest data from its respiratory research pipeline at the Annual International Conference of the American Thoracic Society (ATS 2012), in San Francisco, CA, May 18 - 23. The 14 abstracts include results from a dose-ranging study evaluating tiotropium in subjects with moderate persistent asthma, additional analyses of data from the Phase II TOMORROW trial (To Improve Pulmonary Fibrosis with BIBF 1120), and results from a Phase II trial on the long-acting b2-agonist olodaterol in patients with COPD.
Boehringer Ingelheim’s abstracts in respiratory research can be accessed through the ATS website, http://conference.thoracic.org. The Boehringer Ingelheim data will remain under embargo until the date and time that the data are presented (see details below). The ATS International Conference is one of the largest gatherings of pulmonary, critical care and sleep clinicians and researchers in the world, with 13 thousand attendees from 95 countries last year.
Collectively, these data underscore the company’s focus on finding answers to the challenges faced by patients living with lung disease.
Tiotropium
Title | Lead Author | Presentation details |
Dose-Ranging Study Of Tiotropium As Treatment For Moderate Persistent Asthma In Adolescents | C. Vogelberg | Scientific Abstract# 305
Date: Tuesday, May 22 Time: 8:15 a.m. 10:45 a.m. PDT / 11:15 a.m. 1:45 p.m. EDT |
BIBF 1120
Title | Lead Author | Presentation details |
Treatment Of IPF With The Tyrosine Kinase Inhibitor BIBF 1120: Patient- Reported Outcomes In The TOMORROW Trial | K.K. Brown | Oral Presentation
Date: Monday, May 21 Time: 2:00 p.m 4:30 p.m. (data presented at 2:45 p.m.) PDT / 5:00 p.m. 7:30 p.m. (data presented at 5:45 p.m.) EDT |
Efficacy of the Tyrosine Kinase Inhibitor BIBF 1120 in Patients with IPF: Consistent Pattern of Primary Endpoint Results in Sensitivity Analyses of the TOMORROW trial | L. Richeldi | Oral Presentation
Date: Monday, May 21 Time: 2:00 p.m 4:30 p.m. (data presented at 2:30 p.m.) PDT / 5:00 p.m. 7:30 p.m. (data presented at 5:30 p.m.) EDT |
Olodaterol
Title | Lead Author | Presentation details |
Comparison Of 24-Hour FEV1 Profile For Once- Daily Versus Twice-Daily Treatment With Olodaterol, A Novel Long- Acting b2-Agonist, In Patients With COPD | G. Joos | Thematic Poster # D60
Date: Monday, May 21 Time: 10:45 a.m 12:30 p.m. PDT / 1:45 p.m. 3:30 p.m. EDT |
Lung Function
Title | Lead Author | Presentation details |
Lung Function And Exercise Impairment In Patients With GOLD Stage I And II COPD | D. E. O’Donnell | Thematic Poster # G74
Date: Wednesday, May 23 Time: 8:15 a.m. 4:30 p.m. PDT / 11:15 a.m. 7:30 p.m. EDT Poster Discussion from 10:45 a.m. 12:30 p.m. PDT / 1:45 p.m. 3:30 p.m. EDT |
Boehringer Ingelheim: Leading respiratory forward
Treatment of respiratory diseases has been a major area of focus for Boehringer Ingelheim for more than 90 years and significant resources are dedicated to research in this field. In addition to new possible treatment options for COPD, Boehringer Ingelheim has also branched out into developing treatment options for other airway diseases, including asthma, lung cancer, idiopathic pulmonary fibrosis and other respiratory diseases.
About Boehringer Ingelheim Pharmaceuticals, Inc.
Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim group of companies.
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 44,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.
As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim’s endeavors.
In 2011, Boehringer Ingelheim achieved net sales of about $17.1 billion (13.2 billion euro). R&D expenditure in the business area Prescription Medicines corresponds to 23.5% of its net sales.
For more information, please visit http://us.boehringer-ingelheim.com and follow us on Twitter at http://twitter.com/boehringerus.
SOURCE Boehringer Ingelheim
